Our Product Pipeline: Solid, and Set for Further Growth
Identifying and developing products that will improve the health and quality of life of patients remains a
primary focus of Forest Laboratories. Our current product pipeline includes therapies in all stages of development
and across a wide range of therapeutic areas, including asthma, cardiovascular disease, Alzheimer’s disease, depression, chronic obstructive pulmonary disease, gastrointestinal disease, and infectious disease. The following is a partial
listing of our pipeline products, in alphabetical order:
- Aclidinium for chronic obstructive pulmonary disease
- Aclidinium + Formoterol for chronic obstructive pulmonary disease
- Cariprazine for schizophrenia and bipolar mania
- Ceftaroline acetate for complicated skin and skin structure infections and community acquired pneumonia for hospitalized patients
- Ceftaroline + NXL104 for hospital infections
- Dutogliptin for diabetes
- F2695 for depression
- Linaclotide for chronic constipation and constipation-predominant irritable bowel syndrome (IBS-C)
- Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease
- Nebivolol for congestive heart failure
- Oglemilast for chronic obstructive pulmonary disease and asthma
- RGH-896 for pain
Except for the historical information contained herein, this page contains forward-looking
statements within the meaning of the Private Securities Reform Act of 1995. These
statements involve a number of risks and uncertainties, including the difficulty
of predicting FDA approvals, the acceptance and demand for new pharmaceutical products,
the impact of competitive products and pricing, the timely development and launch
of new products, and the risk factors listed from time to time in Forest Laboratories’
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC
filings.
